

# Summary of Studies Supporting USDA Product Licensure

Establishment Name	Boehringer Ingelheim Animal Health USA Inc.
USDA Vet Biologics Establishment Number	124
Product Code	1181.26
True Name	Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3- Respiratory Syncytial Virus Vaccine, Modified Live Virus
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Boehringer Ingelheim (Canada) Ltd. Pyramid 5 - No distributor specified Pyramid FP 5 - Boehringer Ingelheim (Canada) Ltd.
Date of Compilation Summary	April 08, 2019

### Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

~							
Study Type	Efficacy						
Pertaining to	Bovine Virus Diarrhea (BVD)						
Study Purpose	Demonstration of efficacy against BVD Type 1 clinical disease,						
	leukopenia, and viremia						
<b>Product Administration</b>							
Study Animals	Bovine						
Challenge Description	BVD1b NY-1 strain						
Interval observed after							
challenge							
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.						
USDA Approval Date	June 14, 1994						

	5.00						
Study Type	Efficacy						
Pertaining to	Bovine Virus Diarrhea (BVD)						
Study Purpose	Demonstration of efficacy against persistent infection of calves						
	with BVD Type 1						
<b>Product Administration</b>	Pregnant heifers or cows prior to breeding						
Study Animals	Bovine						
Challenge Description	BVD1b 97B1415 strain						
Interval observed after							
challenge							
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.						
USDA Approval Date	December 10, 2003						

Study Type	Efficacy									
Pertaining to	Bovine Virus Diar	rhea (BVD)								
Study Purpose	Demonstration of	Demonstration of efficacy against BVD Type 1 (respiratory								
	disease) 217 days	after vaccination	n							
Product Administration	One dose, subcuta	neously								
Study Animals	46 bovine calves (	23 vaccinates an	nd 23 controls), 2	25 to 37 days						
	of age			-						
Challenge Description	Challenged with B	SVD Type 1b, Is	olate CA040118	6A, 217 days						
	(7 months) after va	accination								
Interval observed after	Calves were obser	Calves were observed and blood was collected for 14 days after								
challenge	challenge to evalu	ate viremia and	leukopenia.							
Results	Results of the stud	ly are summariz	ed as follows:							
	Blood was evaluat leukopenia (at leas pre-challenge base <b>Positive for V</b>	st one white bloc	od cell count belo	/						
		Viremia	Leukopenia							
	Vaccinates	0/23 (0%)	6/23 (26%)							
	Controls	21/23 (91%)								
	See tables on the following pages for data.									
USDA Approval Date	July 14, 2014									

Animal						Da	ys P	ost-C	Chall	enge					Overall
ID	1	2	3	4	5	6	7	8	9	10	11	12	13	14	Result
21	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
49	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
51	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
57	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
61	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
64	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
67	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
68	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
73	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
82	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
86	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
87	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
94	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
97	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
102	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
104	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
108	I	I	I	-	-	-	-	-	-	-	-	-	-	-	-

# Viremia in Vaccinates (23 bovine)

+ = positive for virus (highlighted yellow)

- = negative for virus

Animal						Da	ys Po	ost-C	halle	enge					Overall
ID	1	2	3	4	5	6	7	8	9	10	11	12	13	14	Result
31	-	-	-	-	-	+	+	-	+	-	-	-	-	-	+
33	-	-	-	-	-	+	-	-	-	-	-	-	-	-	+
36	-	+	+	+	-	+	-	-	-	-	-	-	-	-	+
38	-	-	-	+	+	+	+	-	+	-	-	-	-	-	+
44	-	-	-	+	+	+	-	-	-	-	-	-	-	-	+
47	-	-	-	+	+	-	-	-	-	-	-	-	-	-	+
50	-	-	-	-	-	+	+	-	-	-	-	-	-	-	+
53	-	-	-	-	+	+	+	+	+	-	-	-	-	-	+
56	-	-	-	+	+	+	+	-	-	-	-	-	-	-	+
58	-	-	-	+	+	+	+	-	-	-	-	-	-	-	+
59	-	-	-	+	+	+	+	+	+	-	-	-	-	-	+
62	-	-	-	-	+	-	+	-	-	-	-	-	-	-	+
66	-	-	-	-	+	+	-	+	-	-	-	-	-	-	+
69	-	-	-	-	+	-	-	-	-	-	-	-	-	-	+
70	-	-	-	-	+	+	+	-	-	-	-	-	-	-	+
74	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
85	-	-	-	-	+	+	-	-	-	-	-	-	-	-	+
89	-	-	-	-	+	+	+	-	-	-	-	-	-	-	+
92	-	-	-	-	-	+	+	-	-	-	-	-	-	-	+
98	-	-	-	-	+	+	+	-	-	-	-	-	-	-	+
101	-	-	-	-	-	+	+	+	-	-	-	-	-	-	+
106	-	-	-	-	+	-	-	-	-	-	-	-	-	-	+
107	-	-	-	-	+	+	+	-	-	-	-	-	-	-	+

# Viremia in Controls (23 bovine)

+ = positive for virus (highlighted yellow)

- = negative for virus

				WI	nite Blo	ood Ce	ll Cour	t per e	ach Da	y Post	-Challe	enge				Overall
ID	Base -line	1	2	3	4	5	6	7	8	9	10	11	12	13	14	Result
21	13.5	10.4	11.3	11.6	11.9	11.3	12.4	12.2	11.6	12.4	9.6	9.6	9.3	9.7	10.4	-
32	8.4	8.1	7.8	7.9	NA	9.9	8.9	9.7	8.9	7.1	6.6	8	8.4	10.7	12	-
34	8.9	8.7	9	9.3	9.5	8.5	8.9	9	8.6	8	8.2	4.7	5.1	6.9	8.6	+
37	13.9	12.4	12.7	12.6	11.9	11.6	11	11.4	9.4	9.3	9	9.9	10.1	10.1	9.9	-
41	8.1	8.3	7.8	9.1	8.3	7.5	7.3	7.4	7.5	5.4	5.3	5.1	6.2	7.8	8.1	-
43	8.0	7.7	8	8.8	8.1	8.6	8	8.9	7.8	8.2	6	6.9	8.1	7.4	6.8	-
48	6.2	6.6	6.8	7	6.7	6.5	6.5	6.8	7.2	3.1	3.8	5	5.6	5.8	6.1	+
49	11.1	10.6	10.9	11.1	11.8	10.5	9.4	10.1	10.4	10.5	8	8.8	8.6	10.9	11.9	-
51	8.0	8.5	9.4	10.8	10.4	11.3	9.7	10.1	10.3	8.7	5.5	6.7	7.4	7.5	8.2	-
57	8.5	9.4	9.6	9.1	9.7	8.8	9.4	9.1	9	8.8	8.4	7	8	7.5	7.3	-
61	7	7	6.8	7.9	4.6	3.9	4.5	6.6	7	6.8	6.3	8.2	8.8	8	7.9	+
64	8.1	6.6	6.1	6.6	7.2	6.2	6.9	7.2	7.1	7.4	7.1	6.8	7.8	9.5	9	-
67	6.2	5.8	5.9	6.6	6.7	6.3	3.5	4.7	5	5.1	5.4	6.4	6.4	8.2	6.1	+
68	7.6	8.2	8.5	8.7	8.7	7	5.1	5.6	6.3	6.6	7.2	7.9	8.1	9.3	9.4	-
73	8.0	8	7.9	8	8.1	7.8	7.7	6.1	5.7	5.8	5.9	6.1	7.3	7.4	9.2	-
82	11.6	11.1	11.2	17.2	12.1	11.6	11.6	11	11.5	11.4	5.7	8.1	9.6	11.5	10.8	+
86	6.6	7.2	7.1	6.8	6.8	5.9	6.3	6.1	5.8	6.7	4.2	4.6	5.9	5.9	7.2	-
87	9.2	9.4	9.9	10	7.4	8.3	7.5	10.4	8.8	8.6	9.7	9.1	8.9	9.1	9.6	-
94	11.6	11.2	11.4	10.6	10.1	9.3	9.3	9.4	9.9	10.2	8.3	8.6	9.4	11.4	11.8	-
97	6.4	6.8	7	8.1	8.3	7.7	7.4	7.9	8.3	7.5	4.8	5.3	5.7	6.6	5.8	-
102	8.7	8.3	8.8	8.7	8.9	8.2	8.2	8.5	8	6	3.8	5.5	6.3	7.1	8.1	+
104	8.3	8.4	8.6	9.2	8.9	7.9	8.1	8.9	8.5	6.9	5.3	6.7	6.7	9.9	7.9	-
108	8.1	8.1	9	7.7	8.4	11.4	7.8	9.3	11.9	10.3	10.3	8	12.7	10.6	10.2	-

### Leukopenia in Vaccinates (23 bovine)

#### White Blood Cell Count:

- Baseline is the average white blood cell (WBC) counts from 3 consecutive days, prior to challenge
- Numerical values = white blood cell count in  $K/\mu L$
- Highlighted yellow = positive for leukopenia, meaning a 40% or more reduction in the total WBC count compared to baseline on that day
- NA = not applicable / no measurement on that day

#### **Overall Result:**

- + = positive for leukopenia at least one day (highlighted yellow)
- = negative for leukopenia on every day

				W	hite Blo	ood Ce	ll Cour	t per e	ach Da	y Post	-Challe	enge				Overall
ID	Base -line	1	2	3	4	5	6	7	8	9	10	11	12	13	14	Result
31	7.8	7.7	7.3	3.8	NA	4.5	3.7	3.9	6.1	10.6	7	5.9	5.5	5.9	3.2	+
33	11.3	10.5	11.9	6.5	7	7.3	5.7	6	10.3	7.9	6.8	7	7.4	8.1	7.7	+
36	8.9	9.2	8.8	5.1	6.4	5.7	5.3	5.2	6.6	7.5	6.3	5.7	5.9	5.9	6	+
38	6.5	5.9	7	4.6	4.6	3.9	3.6	3.4	7	7.3	6.1	5.4	5.3	5.6	5	+
44	10.3	10.2	10	4.1	6.2	5.8	4.3	7.3	12.7	8	5.4	5.7	6.3	5.5	5.5	+
47	7.9	8.1	7.6	4.8	5.9	5.8	4.5	5.3	7.9	6.5	6.2	5.8	5.6	5.6	6	+
50	8.2	8.9	8.9	5.9	4.6	6	5.1	6.3	10.4	8.9	6.3	5.1	5.1	5.7	5.6	+
53	7.5	8.3	8.5	3.9	4.5	4.3	3.1	3.4	3.6	7.5	6.1	4.4	5.6	5.8	5.5	+
56	9.8	7.6	9.1	3.9	6	4.5	4.4	5.3	12.2	9.8	5.4	5.2	6	5.5	6.3	+
58	8.3	8.7	9.8	5.7	6.3	7.1	5.1	5.2	8.2	8.4	6.1	6.4	7.4	6.2	6.5	-
59	10.1	11.1	12.2	8.5	7.3	8.7	7.6	7.8	9.4	12.7	13	9.9	9.5	9.9	21.6	-
62	9.5	10.2	9.8	4.9	5.5	5.1	4.2	3.9	7.5	10.7	8.6	7	6.1	6.2	5.5	+
66	6.7	8.5	8	4.5	6	5.2	4.5	5.8	7	5.8	4.8	4.6	5.1	5.4	3.9	+
69	11.1	12.1	11.4	5.1	8.1	8.8	7.2	9.4	11.3	10.5	7.8	7.4	7.1	7.4	7.7	+
70	10.7	10.1	9	4.4	6	5.8	4.4	4.5	7.5	10.8	8.5	7.4	5.6	6.4	5.8	+
74	5.8	6.2	6.4	4.2	4.7	4.2	3.3	3	4	7	5.2	4.4	4.6	4.1	4.5	+
85	8.6	8	7.8	5.7	6.8	5.4	4.5	4.3	5	6.1	6.3	7.4	7.2	7.6	7.4	+
89	8.9	8.4	8.5	3.9	5.8	6.1	4.6	4.1	9.1	8.6	5.7	4.7	5.2	5.1	5.7	+
92	7.8	7.4	5.9	4.4	4.6	3.8	3.2	3.6	4.1	4.6	3.6	3.8	3.8	4.5	4.4	+
98	7.9	7.4	8	4.5	5.9	4.2	4.1	4.1	6.5	7.3	6.5	5.8	6.1	5.9	5.8	+
101	9.9	9.3	10.5	8.5	7.6	7.2	5.6	5.5	5.3	13.4	9.6	7.2	6.5	7	5.4	+
106	7.1	7.2	7.3	4.4	5.3	4.6	3.7	5.2	7.6	5.3	5.1	6.4	5.6	6.3	6.9	+
107	10.7	10.5	10.1	6.7	7.9	7	5.5	5.7	7.8	8.9	8.7	7.5	7.1	7.6	8.8	+

### Leukopenia in Controls (23 bovine)

#### White Blood Cell Count:

- Baseline is the average white blood cell (WBC) counts from 3 consecutive days, prior to challenge
- Numerical values = white blood cell count in  $K/\mu L$
- Highlighted yellow = positive for leukopenia, meaning a 40% or more reduction in the total WBC count compared to baseline on that day
- NA = not applicable / no measurement on that day

#### **Overall Result:**

- + = positive for leukopenia at least one day (highlighted yellow)
- = negative for leukopenia on every day

	7.00						
Study Type	Efficacy						
Pertaining to	Bovine Virus Diarrhea (BVD)						
Study Purpose	Demonstration of efficacy against persistent infection of calves						
	with BVD Type 2						
<b>Product Administration</b>	Pregnant heifers or cows prior to breeding						
Study Animals	Bovine						
Challenge Description	BVD2a 96B2222 strain						
Interval observed after							
challenge							
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.						
USDA Approval Date	December 10, 2003						

Study Type	Efficacy							
Pertaining to	Bovine Virus Diarrhea (BVD)							
Study Purpose	Demonstration of efficacy against BVD Type 2clinical disease,							
	leukopenia, and viremia							
<b>Product Administration</b>								
Study Animals	Bovine							
Challenge Description	BVD2a IAF 103, BT-4A-2 strain							
Interval observed after								
challenge								
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.							
USDA Approval Date	August 4, 2003							

Study Type	Efficacy						
Pertaining to	Infectious Bovine Rhinotracheitis (IBR)						
Study Purpose	Demonstration of efficacy against IBR (respiratory disease)						
Product Administration							
Study Animals	Bovine						
Challenge Description							
Interval observed after							
challenge							
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.						
USDA Approval Date	September 9, 1994						

Study Type	Efficacy
Pertaining to	Bovine Parainfluenza Type 3 (PI <sub>3</sub> )
Study Purpose	Demonstration of efficacy against PI <sub>3</sub>
Product Administration	
Study Animals	Bovine
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	June 10, 2002

Study Type	Efficacy
Pertaining to	Bovine Respiratory Syncytial Virus (BRSV)
Study Purpose	Demonstration of efficacy against BRSV
Product Administration	
Study Animals	Bovine
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	June 14, 1994

Study Type	Safety
Pertaining to	All fractions
Study Purpose	To demonstrate safety under field conditions
Product Administration	
Study Animals	Bovine
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	December 10, 2002

Study Type	Safety
Pertaining to	All fractions
Study Purpose	To demonstrate safety under field conditions
Product Administration	
Study Animals	Bovine: pregnant cows and calves nursing pregnant cows provided
	the cows were vaccinated pre-breeding
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	December 6, 2005